Detalhe da pesquisa
1.
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Pharmacoeconomics
; 41(12): 1641-1655, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37572261